323 related articles for article (PubMed ID: 23975702)
1. The role of generic medicines and biosimilars in oncology in low-income countries.
Renner L; Nkansah FA; Dodoo AN
Ann Oncol; 2013 Sep; 24 Suppl 5():v29-32. PubMed ID: 23975702
[TBL] [Abstract][Full Text] [Related]
2. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
[TBL] [Abstract][Full Text] [Related]
3. Economic perspective of cancer treatment in India.
Natarajan A; Mehra N; Rajkumar T
Med Oncol; 2020 Oct; 37(11):101. PubMed ID: 33057841
[TBL] [Abstract][Full Text] [Related]
4. Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.
Mellstedt H
Ann Oncol; 2013 Sep; 24 Suppl 5():v23-8. PubMed ID: 23975701
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in Oncology in the United States: A Review.
Nabhan C; Parsad S; Mato AR; Feinberg BA
JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
[TBL] [Abstract][Full Text] [Related]
6. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
Bennett CL; Sartor OA; Armitage JO; Kantarjian H
Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
[No Abstract] [Full Text] [Related]
8. Generics and Biosimilars: Barriers and Opportunities.
Scheckel CJ; Rajkumar SV
Mayo Clin Proc; 2021 Dec; 96(12):2947-2957. PubMed ID: 34728057
[No Abstract] [Full Text] [Related]
9. Biosimilars in the Caribbean--key considerations.
Cox SD
West Indian Med J; 2012 Dec; 61(9):849-52. PubMed ID: 24020222
[No Abstract] [Full Text] [Related]
10. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
11. [Can we transfer the mechanisms of the generics market to biosimilars?].
Jacke CO; Wild F
Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
[TBL] [Abstract][Full Text] [Related]
12. International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care.
Frazer MB; Bubalo J; Patel H; Siderov J; Cubilla M; De Lemos M; Dhillon H; Harchowal J; Kuchonthara N; Livinalli A; Macedo R; Mwangi W; Nomura H; O'Connor S; Patterson M; Seadi Torriani M; Yim B; Chan A; Foreman E
J Oncol Pharm Pract; 2020 Apr; 26(3_suppl):3-10. PubMed ID: 32268831
[TBL] [Abstract][Full Text] [Related]
13. Developing oncology biosimilars: an essential approach for the future.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
[TBL] [Abstract][Full Text] [Related]
14. [The development of biosimilars in oncology].
Jiang SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
[TBL] [Abstract][Full Text] [Related]
15. Joint 24th Medicines for Europe and 21st International Generic and Biosimilars Association (IGBA) Annual Conference (June 13-15, 2018 - Budapest, Hungary).
Cross G
Drugs Today (Barc); 2018 Aug; 54(8):499-505. PubMed ID: 30209444
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia-Overview, Evolution, and Regulations Assessment.
Bas TG; Oliu Castillo C
Biomed Res Int; 2016; 2016():5910403. PubMed ID: 27213153
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars: Considerations for Oncology Nurses
.
Vizgirda V; Jacobs I
Clin J Oncol Nurs; 2017 Apr; 21(2):E54-E60. PubMed ID: 28315542
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
19. Regulatory and clinical considerations for biosimilar oncology drugs.
Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
[TBL] [Abstract][Full Text] [Related]
20. Business of biosimilars - 14th annual conference (October 15-17, 2013 - Boston, Massachusetts, USA).
Bourgoin A
Drugs Today (Barc); 2013 Dec; 49(12):799-801. PubMed ID: 24524098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
